All In Biotech

Free tool

FAERS Monitor: Aptiom

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022416 or its brand name (Aptiom, Eslicarbazepine Acetate). Reports on generic versions are filed under their own applications.

Reports

3,321

Serious

2,320

70% of reports

Hospitalization

712

Death reported

98

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • seizure1,014
  • off label use324
  • drug ineffective306
  • dizziness231
  • somnolence193
  • hyponatraemia172
  • fatigue158
  • headache139
  • generalised tonic-clonic seizure118
  • fall117
  • nausea106
  • therapy interrupted100
  • rash98
  • product use in unapproved indication96
  • feeling abnormal94

Reports by year received

View as table
YearReports
20101
20113
20124
20134
201434
2015123
2016164
2017247
2018326
2019397
2020288
2021397
2022270
2023266
2024343
2025267
2026187

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,838 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
seizureSignal1,01456.153.354,621
generalised tonic-clonic seizureSignal11845.538.15,056
hyponatraemiaSignal17219.416.82,982
therapy interruptedSignal1008.97.3692
somnolenceSignal1936.15.3820
dizzinessSignal2312.92.6300
feeling abnormalSignal942.52.083
product use in unapproved indicationSignal962.52.082
off label useSignal3242.32.1259
fallSignal1172.21.979
drug ineffective3061.51.349
rash981.41.212
headache1391.41.216
fatigue1581.31.110
nausea1060.80.73

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.